Skip to content
Dx

ICD-10-CM 2027 diagnosis code

C69.52Malignant neoplasm of left lacrimal gland and duct

✓ Billable / specific

C69.52 is a valid, billable ICD-10-CM code for malignant neoplasm of left lacrimal gland and duct. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.

Code unchanged since ICD-10-CM took effect on October 1, 2015. Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data

About C69.52

C69.52 is the ICD-10-CM diagnosis code for malignant neoplasm of left lacrimal gland and duct. It belongs to category C69 (malignant neoplasm of eye and adnexa), block C69-C72 (malignant neoplasms of eye, brain and other parts of central nervous system) and chapter 2 (neoplasms). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Within C69.5 (malignant neoplasm of lacrimal gland and duct), C69.52 is specifically for malignant neoplasm of left lacrimal gland and duct. Related codes cover unspecified lacrimal gland and duct (C69.50) and right lacrimal gland and duct (C69.51).

It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.

In MS-DRG v44.0, it is part of the grouping logic for DRG 124 (Other Disorders of the Eye with MCC or Thrombolytic Agent, relative weight 1.2471) and DRG 125 (Other Disorders of the Eye without MCC, relative weight 0.7702), in MDC 02 (Diseases and Disorders of the Eye), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It has been part of ICD-10-CM since the code set took effect on October 1, 2015 and hasn't changed since.

Before ICD-10, this condition was coded in ICD-9-CM as 190.2 (malignant neoplasm of lacrimal gland) and 190.7 (malignant neoplasm of lacrimal duct).

Notes that apply from higher levels

Instructions written at a parent level also apply to C69.52.

› From C69 Malignant neoplasm of eye and adnexa
Excludes1
  • malignant neoplasm of connective tissue of eyelid (C49.0)
  • malignant neoplasm of eyelid (skin) (C43.1-, C44.1-)
  • malignant neoplasm of optic nerve (C72.3-)

Broader instructions also apply from Chapter 2: Neoplasms.

MS-DRG v44.0 grouping

All DRGs →

Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.

ICD-9-CM equivalent

Converter →
  • 190.2Malignant neoplasm of lacrimal glandapproximate
  • 190.7Malignant neoplasm of lacrimal ductapproximate

From the CMS 2018 General Equivalence Mappings (GEMs), the final GEMs release.

Code history

  1. 2016
  2. 2017
  3. 2018
  4. 2019
  5. 2020
  6. 2021
  7. 2022
  8. 2023
  9. 2024
  10. 2025
  11. 2026
  12. 2027
  • FY2016 (effective 10/1/2015): Added (first year of ICD-10-CM)
  • No changes since FY2016.

Common questions about C69.52

Is C69.52 billable?

Yes. C69.52 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).

Can C69.52 be used as a principal diagnosis?

Yes. The Medicare Code Editor doesn't restrict C69.52 as a principal diagnosis.

Is C69.52 a CC or MCC?

No. C69.52 is neither a CC nor an MCC under MS-DRG v44.0.

What DRG does C69.52 group to?

C69.52 is used in the MS-DRG v44.0 logic for MS-DRG 124 (Other Disorders of the Eye with MCC or Thrombolytic Agent) and MS-DRG 125 (Other Disorders of the Eye without MCC). Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.

What is the ICD-9 code for C69.52?

The CMS General Equivalence Mappings map C69.52 to ICD-9-CM 190.2 and 190.7.